# Bendamustine Hydrochloride, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

> **NCT01049945** · PHASE1,PHASE2 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 70 (actual)

## Conditions studied

- Refractory Multiple Myeloma

## Interventions

- **DRUG:** bendamustine hydrochloride
- **DRUG:** lenalidomide
- **DRUG:** dexamethasone

## Key facts

- **NCT ID:** NCT01049945
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02
- **Primary completion:** 2012-11
- **Final completion:** 2015-09-16
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2020-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01049945

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01049945, "Bendamustine Hydrochloride, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01049945. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*